Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/148764
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chauffour, Aurélie | en_US |
dc.contributor.author | Robert, Jérôme | en_US |
dc.contributor.author | Veziris, Nicolas | en_US |
dc.contributor.author | Aubry, Alexandra | en_US |
dc.contributor.author | Pethe, Kevin | en_US |
dc.contributor.author | Jarlier, Vincent | en_US |
dc.date.accessioned | 2021-05-17T08:39:55Z | - |
dc.date.available | 2021-05-17T08:39:55Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Chauffour, A., Robert, J., Veziris, N., Aubry, A., Pethe, K. & Jarlier, V. (2020). Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLoS Neglected Tropical Diseases, 14(8). https://dx.doi.org/10.1371/journal.pntd.0007857 | en_US |
dc.identifier.issn | 1935-2727 | en_US |
dc.identifier.uri | https://hdl.handle.net/10356/148764 | - |
dc.description.abstract | Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with a daily combination of rifampin and either injectable streptomycin or oral clarithromycin. An intermittent oral regimen would facilitate treatment supervision. We first evaluated the bactericidal activity of newer antimicrobials against M. ulcerans using a BU animal model. The imidazopyridine amine telacebec (Q203) exhibited high bactericidal activity whereas tedizolid (an oxazolidinone closely related to linezolid), selamectin and ivermectin (two avermectine compounds) and the benzothiazinone PBTZ169 were not active. Consequently, telacebec was evaluated for its bactericidal and sterilizing activities in combined intermittent regimens. Telacebec given twice a week in combination with a long-half-life compound, either rifapentine or bedaquiline, sterilized mouse footpads in 8 weeks, i.e. after a total of only 16 doses, and prevented relapse during a period of 20 weeks after the end of treatment. These results are very promising for future intermittent oral regimens which would greatly simplify BU treatment in the field. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | PLoS Neglected Tropical Diseases | en_US |
dc.rights | © 2020 Chauffour et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | en_US |
dc.subject | Science::Medicine | en_US |
dc.title | Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses | en_US |
dc.type | Journal Article | en |
dc.contributor.school | Lee Kong Chian School of Medicine (LKCMedicine) | en_US |
dc.contributor.school | School of Biological Sciences | en_US |
dc.identifier.doi | 10.1371/journal.pntd.0007857 | - |
dc.description.version | Published version | en_US |
dc.identifier.pmid | 32866170 | - |
dc.identifier.scopus | 2-s2.0-85090520826 | - |
dc.identifier.issue | 8 | en_US |
dc.identifier.volume | 14 | en_US |
dc.subject.keywords | Bedaquiline | en_US |
dc.subject.keywords | Imidazole Derivative | en_US |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
Appears in Collections: | LKCMedicine Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
pntd.0007857.pdf | 1.16 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
20
10
Updated on Mar 25, 2024
Web of ScienceTM
Citations
20
7
Updated on Oct 31, 2023
Page view(s)
223
Updated on Mar 28, 2024
Download(s) 50
51
Updated on Mar 28, 2024
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.